PIFELTRO
Pronunciation: dor-a-VIR-een (pi-FEL-troe)

What it isNon-nucleoside reverse transcriptase inhibitor; HIV.
Why this oneFewer CNS and lipid effects than efavirenz, and it works at high viral load where rilpivirine fails.
What limits itRifampin and other strong inducers are contraindicated. Once daily with or without food.
Animated chart of estimated U.S. prescriptions per year, HIV antiretrovirals (1987–2026). Doravirine enters in 2018 (estimated).
Principal riskStrong inducers such as rifampin are contraindicated
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityAgent-specific renal, hepatic, hematologic, metabolic and drug-interaction toxicity.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| HIV-1 | Adults & peds ≥35 kg | 100 mg QD | 100 mg QD | 100 mg QD |
| HIV-1 with rifabutin | Adults & peds ≥35 kg | 100 mg BID | 100 mg BID | 100 mg BID |
Renal No adjustment (mild–severe); not studied in ESRD/dialysis
Hepatic No adjustment mild–moderate (Child-Pugh A/B); not studied in severe (C)
Available strengths
Pregnancy Pregnancy exposure registry; no adequate human data; no adverse developmental effects in animals at ≥8× human exposure
Lactation Unknown if present in human milk; breastfeeding not recommended (HIV transmission risk)
| Strength | #/mo | generic $/mo | brand $/mo | CostPlus | |
|---|---|---|---|---|---|
| 100 mg | tab | 30 qd | — | $1,823.61 | not offered |
Available combined with: Islatravir
Generic entry2031 est.
Open Doravirine in the interactive console ↗